share_log

Hims & Hers Health | 10-Q: Q2 2024 Earnings Report

Hims & Hers Health | 10-Q: Q2 2024 Earnings Report

Hims & Hers Health | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/06 04:18

Moomoo AI 已提取核心信息

Hims & Hers Health reported strong financial results for Q2 2024, with total revenue increasing 52% year-over-year to $315.6 million. Online Revenue grew 53% to $306.8 million, driven by a 43% increase in subscribers to 1.9 million. The company achieved net income of $13.3 million, compared to a net loss of $7.2 million in Q2 2023, while Adjusted EBITDA reached $39.3 million with a 12% margin.The company demonstrated robust operational execution with Monthly Online Revenue per Average Subscriber increasing to $57, up from $53 in Q2 2023. Average Order Value grew 27% to $121, benefiting from newer offerings and longer duration subscriptions. Gross margin remained healthy at 81%, while operating expenses as a percentage of revenue improved to 78% from 86% last year.Looking ahead, Hims & Hers announced plans to acquire a 503B compounding outsourcing facility for approximately $31 million to expand its compounding capabilities. The Board also authorized a new $100 million share repurchase program through August 2027, following the completion of its previous $50 million program.
Hims & Hers Health reported strong financial results for Q2 2024, with total revenue increasing 52% year-over-year to $315.6 million. Online Revenue grew 53% to $306.8 million, driven by a 43% increase in subscribers to 1.9 million. The company achieved net income of $13.3 million, compared to a net loss of $7.2 million in Q2 2023, while Adjusted EBITDA reached $39.3 million with a 12% margin.The company demonstrated robust operational execution with Monthly Online Revenue per Average Subscriber increasing to $57, up from $53 in Q2 2023. Average Order Value grew 27% to $121, benefiting from newer offerings and longer duration subscriptions. Gross margin remained healthy at 81%, while operating expenses as a percentage of revenue improved to 78% from 86% last year.Looking ahead, Hims & Hers announced plans to acquire a 503B compounding outsourcing facility for approximately $31 million to expand its compounding capabilities. The Board also authorized a new $100 million share repurchase program through August 2027, following the completion of its previous $50 million program.
Hims & Hers Health在2024年第二季度发布了强劲的财务业绩，营业收入同比增长52%，达到31560万美元。在线收入增长53%，达到30680万美元，这得益于订阅用户数增加43%至190万。公司实现了净利润1330万美元，而2023年第二季度净亏损为720万美元，同时调整后的息税折旧摊销前利润（EBITDA）达到了3930万美元，毛利率为12%。公司在运营执行方面表现优异，平均每位订阅用户的每月在线收入增加到57美元，高于2023年第二季度的53美元。平均订单价值增长27%，达到121美元，受益于新产品推出和较长的订阅周期。毛利率保持在健康的81%，而营业费用占营业收入的比例从去年的86%改善至78%。展望未来，Hims & Hers宣布计划以大约3100万美元收购一个5030亿美元的复合外包设施，以扩展其复合能力。董事会还授权了一项新的10000万美元股票回购计划，持续到2027年8月，此前完成了5000万美元的计划。
Hims & Hers Health在2024年第二季度发布了强劲的财务业绩，营业收入同比增长52%，达到31560万美元。在线收入增长53%，达到30680万美元，这得益于订阅用户数增加43%至190万。公司实现了净利润1330万美元，而2023年第二季度净亏损为720万美元，同时调整后的息税折旧摊销前利润（EBITDA）达到了3930万美元，毛利率为12%。公司在运营执行方面表现优异，平均每位订阅用户的每月在线收入增加到57美元，高于2023年第二季度的53美元。平均订单价值增长27%，达到121美元，受益于新产品推出和较长的订阅周期。毛利率保持在健康的81%，而营业费用占营业收入的比例从去年的86%改善至78%。展望未来，Hims & Hers宣布计划以大约3100万美元收购一个5030亿美元的复合外包设施，以扩展其复合能力。董事会还授权了一项新的10000万美元股票回购计划，持续到2027年8月，此前完成了5000万美元的计划。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间